New independent review paper strengthens therapeutic rationale for artelo's fabp inhibitor program in anxiety and depression

Solana beach, calif., june 02, 2025 (globe newswire) -- artelo biosciences, inc. (nasdaq: artl), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, dermatological or neurological conditions, today welcomed the publication of a comprehensive review in neurobiology of disease, titled “fatty acid binding proteins and their involvement in anxiety and mood disorders,” that underscores the therapeutic potential of fatty acid binding protein (fabp) inhibitors in treating mood and anxiety disorders.
ARTL Ratings Summary
ARTL Quant Ranking